SchapiraAHStocchiFBorgohainRet al; for Study 017 Investigators. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20(2):271-280.
6.
BorgohainRSzaszJStanzionePet al; Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229-237.
7.
BorgohainRSzaszJStanzionePet al; Study 018 Investigators. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29(10):1273-1280.
8.
StocchiFBorgohainROnofrjMet al; Study 015 Investigators. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27(1):106-112.
9.
CattaneoCCacciaCMarzoAMajRFarielloRG.Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26(4):213-217.
10.
FarielloRGMcArthurRABonsignoriAet al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998;285(2):397-403.
11.
FarielloRGMajRMarrariPBeardDAlgateCSalvatiP.Acute behavioral and EEG effects of NW-1015 on electrically-induced after discharge in conscious monkeys. Epilepsy Res. 2000;39(1):37-46.
12.
MajRFarielloRGUkmarGet al. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol. 1998;359(1):27-32.
13.
MarzoADal BoLMontiNCet al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50(1):77-85.
14.
Di StefanoAFRuscaA.Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(6):505-515.
15.
KrösserSMarquetAGallemannDet al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos. 2012;33(9):550-559.
16.
SalvatiPMajRCacciaCet al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999;288(3):1151-1159.
17.
Seithel-KeuthAJohneAFreislebenAKupasKLissyMKrösserS.Absolute bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. Clin Pharmacol Drug Dev. 2013;2(1):79-89.
18.
LeurattiCSardinaMVenturaPAssandriAMüllerMBrunnerM.Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-216.
19.
OlanowCWSternMBSethiK.The scientific and clinical basis for the treatment of Parkinson disease. 2009;Neurology. 2009:72(21)(suppl 4):S1-S136.
20.
StocchiFArnoldGOnofrjMet al; Safinamide Parkinson’s Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746-748.
21.
CattaneoCFerlaRLBonizzoniESardinaM.Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475-481.
22.
SchapiraAHFoxSHHauserRAet al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):216-224.
23.
CattaneoCSardinaMBonizzoniE.Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of Studies 016 and SETTLE. J Parkinsons Dis. 2016;6(1):165-173.
24.
CattaneoCBaronePBonizzoniESardinaM.Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95-101.
25.
StocchiFVaccaLGrassiniPet al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(7)(suppl 2):S24-S29.
26.
MarquetAKupasKJohneAet al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012;92(4):450-457.
